Erez Raphael
Known title: Chief Executive OfficerCIK: 0001668046
Erez Raphael's purchase track record
Erez Raphael has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/27/2024 | DRIO | $4K | -20.7% | -18.8% | +5.9% |
| 8/16/2024 | DRIO | $18K | -12.7% | -20.7% | +10.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| DRIO | ▲ Buy | Grant | 297,000 | $0 | 9/24/2026 | View on chart |
| DRIO | ▲ Buy | Grant | 60,000 | $0 | 9/11/2025 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $4K | 8/27/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $5K | 8/21/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $5K | 8/20/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 5,000 | $5K | 8/19/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 2,000 | $2K | 8/16/2024 | View on chart |
| DRIO | ▲ Buy | Open Market | 3,000 | $3K | 8/16/2024 | View on chart |
| DRIO | ▼ Sell | Other | 579 | $11K | 8/12/2024 | View on chart |
| DRIO | ▲ Buy | Grant | 800,000 | $0 | 3/6/2024 | View on chart |
| DRIO | ▼ Sell | Open Market | 1,200 | $7K | 1/13/2023 | View on chart |
| DRIO | ▲ Buy | Grant | 275,000 | $0 | 5/18/2022 | View on chart |
| DRIO | ▼ Sell | Open Market | 800 | $15K | 11/8/2021 | View on chart |
| DRIO | ▼ Sell | Open Market | 200 | $4K | 11/5/2021 | View on chart |
| DRIO | ▼ Sell | Open Market | 7,857 | $145K | 11/4/2021 | View on chart |
| DRIO | ▼ Sell | Open Market | 30,483 | $578K | 11/3/2021 | View on chart |
| DRIO | ▼ Sell | Open Market | 41,279 | $770K | 11/2/2021 | View on chart |
| DRIO | ▼ Sell | Open Market | 25,804 | $465K | 11/1/2021 | View on chart |
| DRIO | ▲ Buy | Grant | 695 | $0 | 10/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
DarioHealth's Aon Analysis Confirms 2.5%-7.2% Cost Reduction
DarioHealth released an independent Aon analysis that backs its estimate of a 2.5%–7.2% reduction in in‑year healthcare costs. The study adds credibility to the company’s cost‑efficiency claims and may influence how analysts view its valuation. The stock is trading near its $7.38 support level, within the 52‑week range of $5.84–$17.74. The analysis could affect investor sentiment as the company continues to pursue its growth strategy.
DarioHealth's Aon Analysis Confirms 2.5%-7.2% Cost Reduction. DarioHealth released an independent Aon analysis that backs its estimate of a 2.5%–7.2% reduction in in‑year healthcare costs. The study adds credibility to the company’s cost‑efficiency claims and may influence how analysts view its valuation. The stock is trading near its $7.38 support level, within the 52‑week range of $5.84–$17.74. The analysis could affect investor sentiment as the company continues to pursue its growth strategy.